Azitra, Inc. (NYSEAMERICAN:AZTR) Sees Large Decline in Short Interest

Azitra, Inc. (NYSEAMERICAN:AZTR) was the recipient of a significant decline in short interest in September. As of September 15th, there was short interest totaling 701,345 shares, a decline of 48.8% from the August 31st total of 1,368,917 shares. Currently, 1.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 510,506 shares, the short-interest ratio is currently 1.4 days.

Azitra Price Performance

Shares of NYSEAMERICAN:AZTR traded up $0.01 during trading on Wednesday, hitting $0.14. 608,668 shares of the stock were exchanged, compared to its average volume of 8,539,169. The company has a fifty day moving average price of $0.15 and a two-hundred day moving average price of $0.19. Azitra has a 12-month low of $0.10 and a 12-month high of $1.09.

Azitra (NYSEAMERICAN:AZTR) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.05). As a group, equities analysts forecast that Azitra will post -0.25 earnings per share for the current fiscal year.

About Azitra

Azitra, Inc is a clinical-stage biotechnology company focused on developing precision dermatology treatments for inflammatory and other skin conditions. The company uses engineered microbes and its proprietary platform to discover and develop live biotherapeutic products intended to address disease-related changes in the skin microbiome and deliver therapeutic proteins locally.

Azitra’s product pipeline has included ATR-12, an engineered strain of Staphylococcus epidermidis designed to produce filaggrin-1 for the potential treatment of Netherton syndrome, a rare genetic skin disorder.